Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia / 中国医学科学杂志(英文版)
Chinese Medical Sciences Journal
; (4): 168-172, 2002.
Article
in En
| WPRIM
| ID: wpr-244855
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>The efficacies of the selective 5-hydroxytryptamine3 (5-HT3) antagonists--ramosetron (0.3 mg) and granisetron (3 mg) in treating acute chemotherapy-induced digestive system dysunction were compared.</p><p><b>METHODS</b>A total of 111 patients were enrolled in a single-blind, randomised crossover study; with data from 98 were used to assess efficacy and data from 110 to assess the safety profile. Ramosetron or granisetron was given intraveneously 15 min befire chemotherpy.</p><p><b>RESULTS</b>The ability of ramosetron to prevent emesis, nausea and anorexia was similar to granisetron during the first 6 h following the administration of chemotherapy, ciplatin or doxorubicin. However, during the first 24 h after chemotherapy, significant differences between ramosetron and granisetron appeared: emetic episode (P = 0.068), nausea (P = 0.006), and anorexia (P = 0.048) remained lower in ramosetron-treated patients. The safety profile of ramosetron was similar to that of granisetron and adverse events in both groups were generally mild and transient.</p><p><b>CONCLUSION</b>Ramosetron is more potent and longer-lasting than granisetron in preventing chemotherapy-induced digestive disturbances.</p>
Full text:
1
Index:
WPRIM
Main subject:
Serotonin Antagonists
/
Benzimidazoles
/
Vomiting, Anticipatory
/
Anorexia
/
Doxorubicin
/
Single-Blind Method
/
Cisplatin
/
Granisetron
/
Cross-Over Studies
/
Therapeutic Uses
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Chinese Medical Sciences Journal
Year:
2002
Type:
Article